Navarra is emerging as one of the most dynamic Biomedical clusters in Spain, and it offers interesting opportunities for investment and association in the sector.

  • The biomedical cluster in Navarra has grown steadily through business initiatives. It consists of more than 30 private companies and research centers that employ more than 2,400 people.
  • Innovation infrastructure in the Region is among the best in Spain and it allows the development of a biomedical product in local throughout all the necessary stages, from discovery to commercialization. This is possible thanks to the networked activity among biomedical companies and institutions established in the Region:
    • Two prestigious universities with a long academic tradition
    • A prestigious public-private health system that is strongly linked to the universities and other stakeholders that promote applied research
    • Navarrabiomed, a publicly funded research center created in 1997 with the aim of promoting biomedical research in the Public Health System of Navarra. The center’s work contributes to the development of translational research and the results are applied in public-sector hospitals.
    • CIMA is the largest private Biomedical research Centre in Spain. It employs more than 400 researchers from over 20 countries and has an annual investment of over 20 million euros.
  • Navarra´s Biomedical cluster is home to some of the most attractive Spanish Biomedical companies, such as:
    • 3P Biopharmaceuticals, the first CMO in Spain
    • CINFA, the leader in generic medicine sales in Spain
    • Idifarma, offers CDMO services to the pharmaceutical sector
    • PaloBiopharma, working on discovering new drugs that modulate adenosine receptors and their development.
    • Albyn Medical, pioneer in the development of medical equipment.
  • The Government of Navarra is strongly committed to the development and consolidation of the biomedical sector in Navarra. The evolution over the last 10 years has been very positive, taking advantage of the pull effect of the biggest generic medicines company in Spain (CINFA) and the ecosystem created around it (3P Biopharmaceutical, Idifarma, Geyser Pharma and Lozys).